Thermo Fisher Scientific
Thermo Fisher Scientific (TMO) is a global leader in laboratory instruments, consumables, and services that support scientific research, healthcare, and industrial applications. With a diversified portfolio across life‑sciences research tools, analytical instruments, specialty diagnostics and laboratory services, the company benefits from recurring consumables and service revenue as well as long‑term demand driven by R&D, healthcare spending and public health needs. Its scale and distribution reach help it serve pharmaceutical, biotech, academic and clinical customers worldwide. Investors should note strengths such as a broad product mix, exposure to steady R&D trends and potential margin resilience from high‑margin consumables, but also risks including integration of acquisitions, regulatory scrutiny, and sensitivity to capital spending cycles. Market cap and valuation can fluctuate; this summary is educational and not personal investment advice. Consider how the company fits your risk profile and investment horizon before making decisions.
Why It's Moving
Thermo Fisher Crushes Q1 Estimates, Fueling Analyst Optimism for 2026 Surge
- Q1 sales beat expectations by 1.5% at $11.01B versus $10.84B forecast, highlighting resilient growth amid healthier end-markets like large pharma and diagnostics.
- Adjusted EPS came in at $5.44, exceeding estimates and underscoring efficient execution and share gains in high-quality segments.
- 2026 guidance projects revenue of $46.3B-$47.2B and EPS of $24.20-$24.80, pointing to accelerated momentum from tools demand and new platforms.
Thermo Fisher Crushes Q1 Estimates, Fueling Analyst Optimism for 2026 Surge
- Q1 sales beat expectations by 1.5% at $11.01B versus $10.84B forecast, highlighting resilient growth amid healthier end-markets like large pharma and diagnostics.
- Adjusted EPS came in at $5.44, exceeding estimates and underscoring efficient execution and share gains in high-quality segments.
- 2026 guidance projects revenue of $46.3B-$47.2B and EPS of $24.20-$24.80, pointing to accelerated momentum from tools demand and new platforms.
When is the next earnings date for Thermo Fisher Scientific (TMO)?
Thermo Fisher Scientific's next earnings announcement is estimated to occur between July 22-24, 2026, covering the company's second quarter results. The exact date has not yet been officially confirmed by the company, with the estimate based on TMO's historical earnings release patterns. Investors should anticipate the report will be released before market open, consistent with the company's recent practice of pre-market announcements followed by a morning conference call. Given that TMO last reported Q1 2026 earnings on April 23, 2026, the Q2 report is expected approximately three months later.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Thermo Fisher's stock with a target price of $642.69, indicating strong potential growth.
Financial Health
Thermo Fisher Scientific is performing well with strong revenue, profits, and cash flow indicators.
Dividend
Thermo Fisher Scientific's low dividend yield of 0.4% indicates limited returns for dividend-seeking investors. If you invested $1000 you would be paid $4 a year in dividends (based on the last 12 months).
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Discover More Opportunities
Abbott
Abbott Laboratories is a global healthcare company that develops and markets a broad range of health care products, including medical devices, diagnostics, nutritionals, and branded generic pharmaceuticals.
ALIGN TECHNOLOGY INC
Align Technology is a medical device company that designs, manufactures and markets a range of dental and orthodontic products.
AVANTOR INC
Avantor, Inc. is a life science tools company and global provider of mission-critical products and services to the life sciences and advanced technology industries. The Company’s segments include Laboratory Solutions and Bioscience Production. Within its segments, it sells materials and consumables, equipment and instrumentation and services and specialty procurement to customers in the biopharma and healthcare, education and government and advanced technologies and applied materials industries. Materials and consumables include ultra-high purity chemicals and reagents, lab products and supplies, highly specialized formulated silicone materials, customized excipients, and others. Equipment and instrumentation include filtration systems, virus inactivation systems, incubators, analytical instruments, and others. Services and specialty procurement include onsite lab and production, equipment, procurement and sourcing and biopharmaceutical material scale-up and development services.
Baskets Featuring TMO
Activist Sparks Life Science Shakeup
Activist investor Engine Capital is pushing for a sale of life-sciences company Avantor after taking a significant stake. This move could spark a wave of M&A across the life-sciences supply industry, creating opportunities for competitor firms and other potential acquisition targets.
Published: August 11, 2025
Explore BasketPharma's American Reshoring Wave
AstraZeneca is investing $50 billion to expand its U.S. manufacturing, partly in response to trade tariffs. This move could spark a wave of similar onshoring efforts, creating opportunities for companies that build, equip, and supply the growing domestic biopharmaceutical industry.
Published: July 23, 2025
Explore BasketDiagnostic Takeover Targets
This carefully selected group of stocks features innovative diagnostic companies that could become acquisition targets following recent takeover interest in the sector. Professional analysts have identified these companies for their unique technologies and established market positions in a consolidating healthcare landscape.
Published: July 15, 2025
Explore BasketEmpire Builders
These companies are led by visionaries who excel at growing through smart acquisitions. Our analysts have carefully selected businesses with proven ability to buy competitors, integrate them successfully, and build lasting market power.
Published: June 17, 2025
Explore BasketPharma
Health is wealth, and these carefully selected pharmaceutical companies could help your portfolio grow. Our professional analysts have handpicked these stocks from an industry that's projected to reach $1.9 trillion by 2027.
Published: May 6, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Recurring Consumables Revenue
Consumables and reagents can create predictable revenue and support margins, though demand can vary with research funding and market cycles.
Global Scientific Reach
A broad international footprint serves diverse customers from pharma to academia, offering resilience but also exposure to regional regulation and economic shifts.
Innovation and Scale
Product innovation and acquisitions expand the addressable market, yet integration and execution risks can affect near‑term results.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
